Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate
- 1 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2869-2875
- https://doi.org/10.1200/jco.2003.12.060
Abstract
Purpose: We investigated the effect of repeated bone-targeted therapy with rhenium-188 hydroxyethylidenediphosphonate (HEDP) in patients with progressive, hormone-resistant prostate carcinoma and bone pain. The aim of this study was to determine the pain palliation and the antitumor effect of rhenium-188 HEDP treatments.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in ChinaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Current clinical trial design issues in hormone-refractory prostate carcinomaCancer, 1998
- Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.Journal of Clinical Oncology, 1998
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancerRadiotherapy and Oncology, 1994
- Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853Cancer, 1993
- Strontium-89--precursor targeted therapy for pain relief of blastic metastatic diseaseCancer, 1993
- Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1993
- A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEuropean Journal of Cancer and Clinical Oncology, 1991